Stereotaxis (NSDQ:STXS) said today it extended a long-term deal with Johnson & Johnson’s (NYSE:JNJ) Biosense Webster to supply it with magnetic ablation catheters.
With the extended deal, St. Louis-based Stereotaxis said it will continue to supply Biosense Webster’s catheters, and will continue to receive a royalty for the sale of those catheters. The deal includes Biosense Webster’s Navistar RMT Thermocool, Navistar RMT, Celsius RMT Thermocool and Celsius RMT, the companies said.
The extension does not modify the company’s existing non-exclusive deal, Stereotaxis said.
“We appreciate the long-term collaboration with Biosense and look forward to continuing to provide the benefits of our joint technologies to patients and physicians in electrophysiology,” chair & CEO David Fischel said in a press release.
Last month, Biosense Webster said it launched its Carto Vizigo bi-directional guiding sheath designed for use with the company’s Carto 3 system in the US.